Phage

Phase 3Biologic

OOttawa Hospital Research Institute

Phage is one of 54 biologic programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Chronic ConstipationActive, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

Chronic ConstipationPreclinical

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

Medrol

Pfizer

Preclinical

12 4

Phage

OOttawa Hospital Research Institute

Phase 3

1 5

Zinbryta

Roche

Preclinical

6 6

Zemplar

AbbVie

Preclinical

2 7

Radicava

Shionogi

Preclinical

1 8

Sensipar

Amgen

Preclinical

1 9

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 10

Cysteine Hydrochloride

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

Treatment Chronic UTI Post Kidney Transplant

Terminated·SShahid Beheshti University of Medical Sciences·Phase 3·NCT05967130·5 enrolled

Periprosthetic Joint Infection1 trial

Use of Phage Therapy for Treatment of a Periprosthetic Joint Infection

Active, not recruiting·OOttawa Hospital Research Institute·Phase 1·NCT06827041·1 enrolled

Chronic constipation1 trial

Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety

Unknown status·SShanghai 10th People's Hospital·N/A·NCT05973721·50 enrolled

Efficacy1 trial

Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes

Withdrawn·—·Phase 1/2·NCT04289948

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Phage. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phage compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phage. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: OOttawa Hospital Research Institute

Phage

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Transplant1 trial

Periprosthetic Joint Infection1 trial

Chronic constipation1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News